ADAPT 2.0 Act Accelerated Drug Approval for Prescription Therapies 2.0 Act
Impact
The enactment of SB1132 is expected to significantly impact the approval process for prescription drugs by allowing more flexibility regarding evidence from foreign studies. Permitting reliance on investigations from countries that meet specific standards could lead to quicker access to medications for American patients, particularly for diseases currently lacking effective treatments. However, it places increased responsibility on the FDA to ensure that these foreign studies meet stringent safety and efficacy standards, raising considerations about maintaining rigorous oversight in drug approvals.
Summary
SB1132, also known as the Accelerated Drug Approval for Prescription Therapies 2.0 Act, aims to streamline the approval process for new drugs by allowing sponsors to rely on clinical investigations conducted in certain foreign countries. This legislation seeks to enhance the speed of bringing new medications to the market, addressing the growing concerns over drug shortages and access to innovative therapies. Specifically, it amends Section 505 of the Federal Food, Drug, and Cosmetic Act to introduce provisions that emphasize the accessibility of foreign clinical data for drug applications, thus potentially shortening the approval timeline to as little as 90 days after submission.
Contention
Key points of contention surrounding SB1132 focus on concerns about safety and the reliability of foreign clinical data. Critics argue that relying on foreign investigations could introduce risks if these studies do not meet the same ethical and scientific standards as required in the United States. There are also worries that the expedited approval process could undermine thorough evaluations of drugs, potentially exposing patients to unsafe medications if the regulatory framework is not adequately protected. Proponents, however, counter that this bill represents a necessary modernization of the drug approval process that could save lives by making timely treatments available.
Reforms the organizational structure for the Department of Transportation and Development including its duties, powers, and responsibilities of officers and employees (EN INCREASE SD EX See Note)
A bill for an act providing for certain business entities acting under the jurisdiction of the secretary of state by providing for the removal of information from a filing based on a sworn affidavit and administrative dissolution based on the response to interrogatories.(See HF 2678.)